or Try an Advanced Search...

    Technical Analysis for LYRA - Lyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.18 -9.04% -0.02
    LYRA closed down 9.04 percent on Wednesday, November 20, 2024, on 4.23 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LYRA trend table...
    Date Alert Name Type % Chg
    Volume Surge Other 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Pocket Pivot Bullish Swing Setup -9.04%
    Volume Surge Other -9.04%
    Lower Bollinger Band Walk Weakness -9.04%
    Wide Bands Range Expansion -9.04%
    Lower Bollinger Band Touch Weakness -9.04%
    Older End-of-Day Signals for LYRA ...

       Recent Intraday Alerts

    Alert Time
    2x Volume Pace about 18 hours ago
    1.5x Volume Pace about 18 hours ago
    3x Volume Pace about 18 hours ago
    Down 5% about 18 hours ago
    Down 3% about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    LYRA Chart by TradingView
    Basic chart:

    Profile

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Sinus Headache Chronic Rhinosinusitis Sinusitis

    Is LYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 13 Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M
    Nov 12 Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
    Nov 12 Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Oct 15 Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
    Sep 27 Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
    Aug 15 Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
    Aug 14 Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
    Aug 14 Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Jul 15 Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?
    See more LYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.79
    52 Week Low 0.1625
    Average Volume 1,575,394
    200-Day Moving Average 1.85
    50-Day Moving Average 0.25
    20-Day Moving Average 0.24
    10-Day Moving Average 0.22
    Average True Range 0.03
    RSI (14) 35.06
    ADX 31.36
    +DI 20.18
    -DI 25.28
    Chandelier Exit (Long, 3 ATRs) 0.22
    Chandelier Exit (Short, 3 ATRs) 0.24
    Upper Bollinger Bands 0.32
    Lower Bollinger Band 0.16
    Percent B (%b) 0.11
    BandWidth 65.75
    MACD Line -0.02
    MACD Signal Line -0.01
    MACD Histogram -0.0094
    Fundamentals Value
    Market Cap 9.36 Million
    Num Shares 52.6 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -0.13
    Price-to-Sales 178.41
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.21
    Resistance 3 (R3) 0.22 0.21 0.21
    Resistance 2 (R2) 0.21 0.20 0.20 0.21
    Resistance 1 (R1) 0.19 0.19 0.19 0.19 0.20
    Pivot Point 0.18 0.18 0.18 0.18 0.18
    Support 1 (S1) 0.17 0.17 0.16 0.17 0.15
    Support 2 (S2) 0.16 0.17 0.16 0.15
    Support 3 (S3) 0.14 0.16 0.15
    Support 4 (S4) 0.14